vs

Side-by-side financial comparison of MESABI TRUST (MSB) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Vivos Therapeutics, Inc. is the larger business by last-quarter revenue ($3.8M vs $3.6M, roughly 1.1× MESABI TRUST). MESABI TRUST runs the higher net margin — 77.1% vs -180.3%, a 257.3% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -95.5%). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs -24.1%).

Mesabi Trust is a United States-based royalty trust that holds permanent royalty interests in iron ore mining properties located in Minnesota's Mesabi Range. It earns revenue primarily from royalty payments tied to the production and sale of iron ore products, with core earnings sourced from active mining partners operating on the land it holds interests in, catering to the global steel manufacturing market.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

MSB vs VVOS — Head-to-Head

Bigger by revenue
VVOS
VVOS
1.1× larger
VVOS
$3.8M
$3.6M
MSB
Growing faster (revenue YoY)
VVOS
VVOS
+98.9% gap
VVOS
3.4%
-95.5%
MSB
Higher net margin
MSB
MSB
257.3% more per $
MSB
77.1%
-180.3%
VVOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
-24.1%
MSB

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
MSB
MSB
VVOS
VVOS
Revenue
$3.6M
$3.8M
Net Profit
$2.8M
$-6.9M
Gross Margin
77.1%
78.1%
Operating Margin
-166.8%
Net Margin
77.1%
-180.3%
Revenue YoY
-95.5%
3.4%
Net Profit YoY
-96.5%
-143.8%
EPS (diluted)
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MSB
MSB
VVOS
VVOS
Q4 25
$3.6M
$3.8M
Q3 25
$5.6M
$6.8M
Q2 25
$4.7M
$3.8M
Q1 25
$6.9M
$3.0M
Q4 24
$79.0M
$3.7M
Q3 24
$6.5M
$3.9M
Q2 24
$6.3M
$4.1M
Q1 24
$6.2M
$3.4M
Net Profit
MSB
MSB
VVOS
VVOS
Q4 25
$2.8M
$-6.9M
Q3 25
$4.7M
$-5.4M
Q2 25
$3.6M
$-5.0M
Q1 25
$6.1M
$-3.9M
Q4 24
$78.3M
$-2.8M
Q3 24
$5.4M
$-2.6M
Q2 24
$3.5M
$-1.9M
Q1 24
$4.7M
$-3.8M
Gross Margin
MSB
MSB
VVOS
VVOS
Q4 25
77.1%
78.1%
Q3 25
84.6%
58.0%
Q2 25
76.7%
55.2%
Q1 25
88.5%
50.0%
Q4 24
99.1%
56.7%
Q3 24
83.2%
60.5%
Q2 24
55.7%
65.4%
Q1 24
75.3%
56.7%
Operating Margin
MSB
MSB
VVOS
VVOS
Q4 25
-166.8%
Q3 25
-69.8%
Q2 25
-127.4%
Q1 25
-129.9%
Q4 24
-75.9%
Q3 24
-68.5%
Q2 24
-47.8%
Q1 24
-110.7%
Net Margin
MSB
MSB
VVOS
VVOS
Q4 25
77.1%
-180.3%
Q3 25
84.6%
-79.6%
Q2 25
76.7%
-131.2%
Q1 25
88.5%
-128.1%
Q4 24
99.1%
-76.4%
Q3 24
83.2%
-67.8%
Q2 24
55.7%
-47.6%
Q1 24
75.3%
-110.1%
EPS (diluted)
MSB
MSB
VVOS
VVOS
Q4 25
$-0.58
Q3 25
$-0.49
Q2 25
$-0.55
Q1 25
$-0.45
Q4 24
$0.41
Q3 24
$-0.40
Q2 24
$-0.60
Q1 24
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MSB
MSB
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$21.1M
$-1.5M
Total Assets
$26.0M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MSB
MSB
VVOS
VVOS
Q4 25
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$6.3M
Q3 24
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
MSB
MSB
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
MSB
MSB
VVOS
VVOS
Q4 25
$21.1M
$-1.5M
Q3 25
$22.8M
$2.5M
Q2 25
$19.6M
$4.6M
Q1 25
$23.3M
$4.4M
Q4 24
$95.3M
$8.0M
Q3 24
$22.1M
$7.7M
Q2 24
$20.7M
$6.3M
Q1 24
$21.0M
$582.0K
Total Assets
MSB
MSB
VVOS
VVOS
Q4 25
$26.0M
$25.2M
Q3 25
$24.8M
$25.6M
Q2 25
$27.4M
$26.0M
Q1 25
$101.7M
$11.3M
Q4 24
$100.7M
$15.3M
Q3 24
$26.2M
$15.3M
Q2 24
$25.1M
$15.8M
Q1 24
$26.7M
$11.8M
Debt / Equity
MSB
MSB
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MSB
MSB
VVOS
VVOS
Operating Cash FlowLast quarter
$3.5M
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
1.27×
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MSB
MSB
VVOS
VVOS
Q4 25
$3.5M
$-3.8M
Q3 25
$4.4M
$-4.2M
Q2 25
$2.1M
$-3.5M
Q1 25
$93.9M
$-3.8M
Q4 24
$78.2M
$-2.9M
Q3 24
$3.8M
$-4.2M
Q2 24
$2.5M
$-3.0M
Q1 24
$14.6M
$-2.5M
Free Cash Flow
MSB
MSB
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
MSB
MSB
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
MSB
MSB
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%
Cash Conversion
MSB
MSB
VVOS
VVOS
Q4 25
1.27×
Q3 25
0.92×
Q2 25
0.57×
Q1 25
15.48×
Q4 24
1.00×
Q3 24
0.71×
Q2 24
0.72×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MSB
MSB

Segment breakdown not available.

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons